<DOC>
	<DOC>NCT01327963</DOC>
	<brief_summary>The purpose of this open-label, postmarket study is to evaluate the safety and efficacy of transoral incisionless fundoplication (TIF) performed with EsophyX in a broad range of gastroesophageal reflux disease (GERD) patients treated at high volume centers across the United States.</brief_summary>
	<brief_title>Retrospective TIF Study for Treatment of Gastroesophageal Reflux Disease (GERD). The RetroTIF Study</brief_title>
	<detailed_description>This open-label, postmarket study evaluates the safety and efficacy of transoral incisionless fundoplication (TIF) performed with EsophyX in a broad range of gastroesophageal reflux disease (GERD) patients treated at high volume centers across the United States, in clinical routine practice, as standard of care.</detailed_description>
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<criteria>Age 1885 years Have undergone the TIF procedure within the past 2 years Availability for a followup visit at 12 or 24 months Willingly and cognitively signed informed consent Procedure not completed or performed following a nonstandardized TIF protocol Subjects suffering from other GI conditions such as dyspepsia, celiac disease, IBS or Crohn's disease Pregnancy Enrollment in another device or drug study that may confound the results</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Gastroesophageal reflux disease</keyword>
	<keyword>GERD</keyword>
	<keyword>Heartburn</keyword>
	<keyword>Reflux</keyword>
	<keyword>Regurgitation</keyword>
	<keyword>Hoarseness</keyword>
	<keyword>Cough</keyword>
</DOC>